BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics


BeyondSpring, Inc. - Ordinary Shares (BYSI): $15.36

-7.55 (-32.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BYSI Stock Price Chart Interactive Chart >

Price chart for BYSI

BYSI Price/Volume Stats

Current price $15.36 52-week high $33.00
Prev. close $22.91 52-week low $8.90
Day low $15.14 Volume 5,014,545
Day high $19.70 Avg. volume 1,319,113
50-day MA $19.31 Dividend yield N/A
200-day MA $13.52 Market Cap 600.67M

BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio


BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.


BYSI Latest News Stream


Event/Time News Detail
Loading, please wait...

BYSI Latest Social Stream


Loading social stream, please wait...

View Full BYSI Social Stream

Latest BYSI News From Around the Web

Below are the latest news stories about BeyondSpring Inc that investors may wish to consider to help them evaluate BYSI as an investment opportunity.

BeyondSpring Presents New Plinabulin Data At ESMO Congress

BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 2021 Congress. Plinabulin combined with G-CSF to prevent CIN is currently under U.S. and China regulatory review with an FDA PDUFA date of November 30. The data showed that the severe neutropenia endpoint is correlated with clinically meaningful endpoints in a meta-analysis with over 7000 patients. Relat

Yahoo | September 16, 2021

BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021.NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of innovative cancer therapeutics, today announced new positive data on plinabulin from its chemotherapy-induced neutropenia (CIN) p

Yahoo | September 16, 2021

BeyondSpring inc (BYSI) Q2 2021 Earnings Call Transcript

Joining us on today's call is Dr. Lan Huang, BeyondSpring's Co-Founder, Chairman and Chief Executive Officer; Dr. Ramon Mohanlal, Executive Vice President, Research and Development and Chief Medical Officer; Richard Daly, Chief Operating Officer; and Elizabeth Czerepak, Chief Financial Officer. It is now my pleasure to turn the call over to Dr. Lan Huang.

Yahoo | September 10, 2021

BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue Estimates

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 0.00% and -97.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | September 10, 2021

BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

- Management to host a call today at 8:00 am ETNEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate events. “We had a very productive first half of 2021. Importantly, we were thrilled to announce positive data from our reg

Yahoo | September 10, 2021

Read More 'BYSI' Stories Here

BYSI Price Returns

1-mo -23.92%
3-mo 36.65%
6-mo 39.64%
1-year 0.85%
3-year -38.56%
5-year N/A
YTD 25.90%
2020 -21.29%
2019 -17.33%
2018 -35.52%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 3.0225 seconds.